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Abstract
Background: Increasing prevalence of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae (ERE) in Singapore
presents a major therapeutic problem. Our objective was to determine risk factors associated with the acquisition of ERE in
hospitalized patients; to assess associated patient outcomes; and to describe the molecular characteristics of ERE.
Methods: A retrospective case-case-control study was conducted in 2009 at a tertiary care hospital. Hospitalized patients
with ERE and those with ertapenem-sensitive Enterobacteriaceae (ESE) were compared with a common control group
consisting of patients with no prior gram-negative infections. Risk factors analyzed included demographics; co-morbidities;
instrumentation and antibiotic exposures. Two parallel multivariate logistic regression models were performed to identify
independent variables associated with ERE and ESE acquisition respectively. Clinical outcomes were compared between ERE
and ESE patients.
Results: Twenty-nine ERE cases, 29 ESE cases and 87 controls were analyzed. Multivariate logistic regression showed that
previous hospitalization (Odds ratio [OR], 10.40; 95% confidence interval [CI], 2.19–49.20) and duration of fluoroquinolones
exposure (OR, 1.18 per day increase; 95% CI, 1.05–1.34) were unique independent predictors for acquiring ERE. Duration of
4
th-generation cephalosporin exposure was found to predict for ESE acquisition (OR, 1.63 per day increase; 95% CI, 1.05–
2.54). In-hospital mortality rates and clinical response rates were significantly different between ERE and ESE groups,
however ERE infection was not a predictor of mortality. ERE isolates were clonally distinct. Ertapenem resistance was likely to
be mediated by the presence of extended-spectrum b-lactamases or plasmid-borne AmpC in combination with
impermeability due to porin loss and/or efflux pumps.
Conclusion: Prior hospitalization and duration of fluoroquinolone treatment were predictors of ERE acquisition. ERE
infections were associated with higher mortality rates and poorer clinical response rates when compared to ESE infections.
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Introduction
Extended-spectrum b-lactamases (ESBL)-producing Enterobacte-
riaceae are major contributors to the mounting gram-negative
resistance problem globally [1]. Carbapenems are often the only
remaining therapeutic options available for these serious ESBL-
producing Enterobacteriaceae infections [2]. Unfortunately, carbape-
nem resistance has also emerged as a result of selective pressure on
Enterobacteriaceae [3]. Whilst Singapore is not spared from this
emergence, it is fortunate that overall rates of susceptibility to
carbapenems remained fairly stable [4]. However, since 2006,
systemic surveillance of hospitals unexpectedly detected an
increasing prevalence of Klebsiella pneumoniae and Escherichia coli
clinical isolates that were resistant to ertapenem, but susceptible to
group II carbapenems [5]. This coincided with the increasing
popularity of ertapenem as a treatment option for ESBL- and
AmpC-producing Enterobacteriaceae infections, in spite of the lack of
prospective comparative trials investigating its use in such
infections.
Carbapnem resistance may be mediated by carbapenemases or
metallo-b-lactamases [6]; or due to a combination of ESBL or
AmpC b-lactamase production with impermeability caused by
porin loss [7–10]. Enterobacteriaceae exhibiting low-level resistance to
ertapenem, a Group I carbapenem, may still remain susceptible to
Group II carbapenems such as imipenem and meropenem. The
underlying resistance mechanisms in these unique ertapenem-
resistant Enterobacteriaceae appear to differ from those isolates with
universal resistance to all carbapenems – ertapenem permeability
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II carbapenems and ertapenem resistance is seldom carbapene-
mases-mediated [7,11,12].
The clinical epidemiology of these ertapenem-resistant, Group
II carbapenem-susceptible Enterobacteriaceae (ERE) is poorly under-
stood. There have been several reports regarding the risk factors
for acquisition of carbapenem-resistant Enterobacteriaceae [13–19],
but less so for ertapenem resistance in particular [20,21]. The
intent of this study was to identify the risk factors associated with
the acquisition of ERE among hospitalized patients, to compare
the outcomes of patients with ERE with those with ertapenem-
susceptible Enterobacteriaceae (ESE) infections, and to describe the
molecular profile of ERE locally. Identification of factors
contributing to the emergence of ERE among the hospitalized
population is crucial in the design of effective strategies to prevent
the development of such infections, as well as to avoid therapy
failure by precluding empiric ertapenem use in this risk
population.
Materials and Methods
Study setting
The study was conducted at Singapore General Hospital, a
1,600-bedded acute tertiary care hospital between January 2009 to
September 2009. The hospital is the largest of six public
healthcare hospitals, and accounted for approximately 35% of
recorded inpatient-days among them. Infection control policies
remained unchanged during the study period. ERE prevalence
remained stable and there was no indication of an outbreak during
this period. Surveillance cultures to detect asymptomatic ERE
colonization were not routinely performed in the institution. The
study was reviewed and approved by the Singhealth institutional
ethics review board. As this was a retrospective study, the need for
an informed consent was waived by the ethics review board.
Study design
A retrospective parallel case-control study design was used to
identify risk factors associated with the acquisition of ERE. The
case-case-control design overcomes several limitations of the
standard case-control design, particularly studies where patients
infected with ‘‘susceptible phenotype’’ are elected as controls. In
such case-control studies, effect measures of antibiotics active
against the susceptible, but not the resistant phenotype, could be
falsely inflated since the administration of these antibiotics close to
the time of culture would have prevented the recovery of the
susceptible phenotype, hence excluding these patients from the
control group. The other advantages of the case-case-control
methodology are described in detail elsewhere [22,23].
The computerized records of the hospital’s clinical microbio-
logical laboratory were used to identify all clinical cultures positive
for Enterobactaeriaceae. The first case group consisted of all adult
inpatients (.18 years old) with microbiological cultures positive
for ERE, regardless of whether the culture reflected a clinically-
relevant infection or colonization. The second case group
consisted of adult inpatients with microbiological cultures positive
for ESE recorded within the same study period. In order to ensure
that the two parallel case-control models were comparable, an
equal number of (i) Enterobacteriaceae species type and (ii) specimen
type were selected for each case group. Patients who had multiple
cultures positive for Enterobacteriaceae were included only once and
the ‘‘index’’ culture is the first Enterobacteriaceae specimen recorded
during the stay that qualified each patient for inclusion into the
two case groups.
Control group patients were adult inpatients admitted within
the study period with no history of prior infection with
Enterobacteriaceae or other gram-negative bacilli, but could have
gram-positive infections. Three control patients were randomly
identified and chosen from the hospital’s computerized adminis-
trative source records for each ERE/ESE case patient.
An independent observer (a research assistant), blinded to the
study’s hypothesis/objectives, performed random selection of ESE
case and control patients based solely on the respective inclusion
and exclusion criteria provided to him. The first patient listed in
the database who met the study criteria was selected and this
process was continued until all ESE cases and controls patients
were identified.
Data collection
Data were sought from inpatient charts, electronic medical
records, clinical microbiology laboratory computerized databases
and collated in a structured data collection form by three trained
reviewers. Variables analyzed as risk factors included: 1)
demographics (age, gender); 2) presence of comorbid conditions
and Charlson weighted co-morbidity index; 3) severity of illness as
determined by APACHE II score; 4) hospitalization history such
as previous hospital and nursing home stay, previous ICU stay,
length of hospital stay prior to outcome of interest (defined as
length of stay prior to Enterobacteriaceae isolation for case patients
and total length of stay for controls); 5) exposure to invasive
interventions (central lines, urinary catheters, drainage devices,
invasive ventilation, dialysis, non-surgical invasive procedures such
as endoscopic procedures, invasive surgery, dialysis); 6) receipt of
immunosuppressive therapy (defined as receipt of .one dose of
chemotherapy or immunosuppressants, or .14 days of cortico-
steroids at an equivalent daily dose of 20 mg prednisolone) and 7)
antibiotics exposure (receipt of $one dose of various classes of
antimicrobials). The number of invasive devices and cumulative
duration of antibiotics were also tabulated. All variables were
evaluated for an interval of 90 days prior to the occurrence of
ERE/ESE for case patients or end of hospitalization for control
patients.
A retrospective cohort study involving the same groups of ERE
and ESE patients were conducted in order to evaluate the impact
of ERE on clinical outcomes. All ERE and ESE patients who were
considered having clinically relevant infections were included for
outcome analyses. Infection was considered clinically relevant if
Enterobacteriaceae were isolated from clinical specimens obtained
from sterile sites (e.g. blood or pleural effusion); or if there was a
presence of clinical symptoms or signs of infection consistent with
the infecting Enterobacteriaceae; or antibiotic therapy was adminis-
tered for the Enterobacteriaceae infection. Colonizers were excluded.
For polymicrobial infections, patients were included only if the
presence of ERE or ESE contributed to the decision for antibiotic
treatment. Primary outcomes of interest were: (i) the final end-
points of hospitalization i.e. discharge or mortality (in-hospital all-
cause mortality), (ii) hospital length of stay after infection, (iii) 30-
day readmission (defined as non-elective readmission within 30
days of discharge), and (iv) clinical response (defervescence,
resolution of abnormalities of vital signs and infection markers,
or resolution of symptoms specific to infection). Clinical improve-
ment was presumed if patient was well enough to be discharged in
patients where surrogate infection markers were not documented.
Microbiological methods
Carbapenem susceptibility was determined using disk diffusion
and interpreted in accordance to the 2009 Clinical and Laboratory
Standards Institute guidelines as per hospital’s clinical microbiol-
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and imipenem was part of laboratory’s routine protocol, but not
for meropenem. Enterobacteriaceae isolates with ‘‘intermediate’’ or
‘‘resistant’’ classification for ertapenem, but ‘‘susceptible’’ to class
II carbapenems, were included in ERE case group. Fifteen clinical
isolates were available for further molecular characterization. A
conventional rep-polymerase chain reaction (PCR) method was
used for clonal typing [25]. PCR products were analyzed by chip-
based microfluidic electrophoresis (Experion, Biorad, USA).
Digitalized banding images were exported and cluster analysis
was performed using Bionumerics 5.4 (AppliedMaths, Kortrijk,
Belgium). The isolates were considered as indistinguishable
(similarity of DNA fragment pattern .90%) or distinct (similarity
of DNA fragment pattern ,90%). Resistance gene analyses of
ESBLs, plasmid-mediated AmpC genes, metallo-b-lactamases
(MBLs) and Klebsiella pneumoniae carbapenemase (KPC) were
performed using modified methods from previously published
PCR protocols [26–30].
Statistical Analysis
Catergorical variables were presented as numbers and percent-
ages, and were compared using the X
2 or Fisher exact test, as
appropriate. Continuous variables were presented as mean 6 SD
or median and range, and were compared using the Student’s t
test or the Mann-Whitney test, depending on the validity of the
normality assumption.
In the risk factor analysis, multivariate logistic regression models
were used to compare each case group to control group. Clinically
plausible variables identified in the univariate analysis were
included in a stepwise selection multivariate logistic regression
model if P,0.1. The final model was chosen on basis of biologic
plausibility. Odds ratios (OR) and 95% confidence intervals (CI)
were calculated to evaluate the strength of any association. Results
from the ERE-control model were compared with the ESE-control
model to identify significant factors unique to each case group. In
the outcomes analysis, ERE and ESE patients who died were
compared with those who survived in order to determine risk
factors predicting for in-hospital mortality via univariate and
subsequently multivariate logistic regression analysis.
For all calculations, a 2-tailed P value of less than 0.05 was
considered to reveal a statistical significant difference. Statistical
analyses were performed using SPSS 17.0 (SPSS, Chicago, IL,
USA).
Results
Study population
During the study period, 29 patients with ERE, 29 patients with
ESE and 87 controls were identified. Of the ERE species included
in the study, Klebsiella spp. (16/29, 55.2%) was most commonly
identified, while Escherichia coli (5/29, 17.2%) and Enterobacter spp.
(8/29, 27.6%) accounted for the remaining ERE species. Urine
(12/29, 41.4%) was the most common site which ERE were
isolated from, followed by blood (6/29, 20.7%), abdominal
tissues/fluids (6/29, 20.7%), respiratory secretions (3/29, 10.3%)
and skin and soft tissue wounds (2/29, 6.9%) (Table 1). Of the 29
ERE isolates, 20 (69.0%) were resistant to ertapenem and 9
(31.0%) were intermediate. These ERE isolates exhibited multi-
drug resistance – 100% was resistant to ceftriaxone and
amoxicillin-clavulanate; 97% to piperacillin-tazobactam; 79% to
ciprofloxacin; and 76% to cefepime. However, ERE remained
relatively susceptible to amikacin (3% resistant) and gentamicin
(41% resistant).
The demographic characteristics and co-morbidities of the case
and control patients are shown in Table 2. Overall, ERE and ESE
case patients were fairly similar in baseline characteristics to the
control group respectively. However, ERE patients were more
likely to have cardiovascular and hepatic diseases, while ESE
patients were older, more likely to have hepatic and renal diseases
and had a higher Charlson co-morbidity index, when compared to
the control group.
Comparing ERE cases to controls, ERE patients were
significantly more likely to have been previously exposed to the
hospital environment and various instrumentation or interven-
tions, and had longer hospital stays prior outcome of interest
(Table 3). Likewise ESE patients had longer hospital stays prior
outcome of interest when compared to controls. However, unlike
ERE cases, only exposure to central lines and urinary catheters
were significantly different between the ESE and control groups.
More than 70% of patients in each group received some form of
antibiotic in the 90 days prior to the outcome of interest (Table 4).
ERE patients received significantly longer durations of all classes of
antibiotics investigated, with the exception of penicillin, when
compared to controls. In contrast, there were no significant
differencesinantibioticexposuresbetweenESEpatientsandcontrols,
with the exception of the receipt of 4
th-generation cephalosporins.
Risk factor analysis
The results for the multivariate analyses of the ERE-control and
ESE-control models are presented in Table 5. When the two
models were contrasted, previous hospital stay and longer
exposures of fluoroquinolone use were unique significant predic-
tors of ERE acquisition, while duration of exposure to 4
th-
generation cephalosporins was the only unique significant
predictor of ESE acquisition.
Outcomes Analysis
Twenty-six patients with ERE and 27 patients with ESE were
considered to have clinically-relevant Enterobacteriaceae infections
Table 1. Species, site and resistance mechanisms of ERE
isolates.
Species
E.coli Klebsiella spp. Enterobacter spp.
Site n=5 n=16 n=8
Blood 4 (13.8) 0 2 (6.9)
Urine 1 (3.4) 10 (34.5) 1 (3.4)
Respiratory 0 2 (6.9) 1 (3.4)
Skin/soft tissue 0 0 2 (6.9)
Abdominal 0 4 (13.8) 2 (6.9)
Resistance mechanisms
Isolates tested 1 (20.0) 9 (56.3) 5 (62.5)
SHV 0 8 (88.9) 1 (20.0)
TEM 1 (100.0) 7 (77.8) 1 (20.0)
CTX-M 1 (100.0) 7 (77.8) 1 (20.0)
AmpC 0 6 (66.7) 0
KPC 0 0 0
Metallo-b-lactamase 0 0 0
Data are presented as n(%), unless otherwise stated.
doi:10.1371/journal.pone.0034254.t001
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hospital mortality was significantly higher in the ERE group
(P=0.04) (Table 6). ERE patients also had a poorer clinical
response rate (P=0.04).
Table 7 showed the results of univariate analysis for risk factors
associated with in-hospital mortality among the ERE and ESE-
infected patients. In-hospital mortality was associated with
malignancy, high APACHE II score, isolation of Enterobacteriaceae
in blood and ERE infection. However, none of these variables
remained significant when introduced into the multivariate model.
Molecular characteristics
Fifteen isolates (15/29, 51.7%) were available for further
molecular work-up, which included nine K. pneumoniae, four E.
cloacae, one E. aerogenes and one E.coli (Table 1). Clonality testing of
K. pneumoniae and E. cloacae isolates showed clonally-distinct
populations respectively. Ertapenem resistance was not mediated
by carbapenemases or MBLs in all three species. Overall, 80%
(12/15) of tested isolates had beta-lactamases (TEM-1, SHV-1,
SHV-11, SHV-12, SHV-50, CTX-M-1) or AmpC genes of the
DHA-type alone or in combinations.
Discussion
Infection with carbapenem-resistant Enterobacteriaceae (CRE) is
emerging as an important challenge in health-care settings [31].
While there are a number of studies relating to CRE in general,
information pertaining to ERE is scarcer. Our study evaluated the
Table 2. Baseline demographic characteristics and co-morbidities.
ERE ESE Control ERE versus controls ESE versus controls
(n=29) (n=29) (n=87) OR (95% CI) P OR (95% CI) P
Median age, yr (range) 55 (22–91) 75 (27–88) 65 (18–100) … 0.22 … 0.01
Male sex 12 (41.4) 15 (51.7) 36 (41.3) 1.15 (0.49–2.69) 0.75 1.52 (0.65–3.53) 0.33
Diabetes mellitus 11 (37.9) 15 (51.7) 32 (36.8) 1.05 (0.44–2.50) 0.91 1.84 (0.79–4.30) 0.16
Cardiovascular disease 15 (51.7) 8 (27.6) 25 (28.7) 3.05 (1.28–7.26) 0.01 0.95 (0.37–2.41) 0.91
Hepatic disease 4 (13.8) 5 (17.2) 4 (4.6) 4.32 (1.08–17.37) 0.04 4.32 (1.08–17.37) 0.04
Renal disease 9 (31.0) 12 (41.4) 19 (21.8) 1.61 (0.63–4.11) 0.32 2.53 (1.03–6.20) 0.04
Neurologic disease 6 (20.7) 5 (17.2) 11 (12.6) 1.80 (0.60–5.41) 0.36 1.44 (0.46–4.56) 0.54
Malignancy 8 (27.6) 5 (17.2) 15 (17.2) 1.77 (0.68–4.90) 0.23 1.00 (0.33–3.04) 1.00
Median Charlson score (range)
a 4 (0–13) 6 (0–10) 4 (0–13) … 0.09 … ,0.001
Median APACHE II score, (range)
a 15 (2–30) 15 (2–32) 9 (0–32) … 0.06 … 0.005
The ERE-control model was conducted independently from the ESE-control model.
Data are presented as n(%), unless otherwise stated.
aMeasured on date of culture isolation for case patients and on date of admission for controls.
doi:10.1371/journal.pone.0034254.t002
Table 3. Hospital exposures and instrumentation/interventions as risk factors for ERE infections.
ERE ESE Control ERE versus controls ESE versus controls
(n=29) (n=29) (n=87) OR (95% CI) P OR (95% CI) P
Immunosuppression 7 (24.1) 3 (10.3) 4 (4.6) 6.60 (1.77–24.60) 0.005 2.39 (0.50–11.40) 0.36
Previous hospital stay 23 (79.3) 15 (51.7) 29 (33.3) 7.67 (2.81–20.90) ,0.001 2.14 (0.91–5.03) 0.08
Median length of stay prior to
outcome of interest
a, days(range)
17 (1–85) 3 (1–47) 6 (1–40) … 0.004 … 0.71
Central lines 18 (62.1) 9 (28.1) 8 (9.2) 16.20 (5.69–45.93) ,0.001 4.44 (1.52–12.97) 0.01
Median no of central lines, (range) 1 (0–3) 0 (0–1) 0 (0–2) … ,0.001 … 0.07
Urinary catheter 18 (62.1) 15 (51.7) 18 (20.7) 5.43 (2.20–13.40) ,0.001 4.11 (1.68–10.04) 0.001
Nasogastric tube 11 (37.9) 6 (18.8) 8 (9.2) 5.20 (1.81–14.94) 0.002 2.58 (0.81–8.18) 0.11
Drainage device 13 (44.8) 5 (15.6) 7 (8.0) 8.07 (2.77–23.50) ,0.001 2.38 (0.69–8.19) 0.17
Median no of drainage devices, (range) 0 (0–5) 0 (0–3) 0 (0–3) … 0.01 … 0.16
Surgery 12 (41.4) 8 (25.0) 20 (23.0) 2.37 (0.97–5.77) 0.06 1.28 (0.49–3.32) 0.62
Non-surgical invasive procedure 19 (65.5) 12 (37.5) 26 (29.9) 4.46 (1.83–10.89) 0.001 1.66 (0.69–3.95) 0.25
Invasive ventilation 6 (20.7) 3 (9.4) 3 (3.4) 5.83 (1.30–26.18) 0.02 3.23 (0.62–16.99) 0.16
The ERE-control model was conducted independently from the ESE-control model.
Data are presented as n(%), unless otherwise stated.
aRefers to duration of hospital stay prior to culture isolation for cases and entire duration of hospital stay for controls.
doi:10.1371/journal.pone.0034254.t003
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hospitalized patients. We found that previous hospital stay and
increased durations of prior fluoroquinolone therapy appeared to
be associated with ERE acquisition. In addition, higher mortality
rates and poorer clinical response rates were observed in ERE-
infected patients.
Only two case-control studies investigating ERE have been
published. Risk factors implicated in these studies included: ICU
stay, exposure to invasive medical devices, and antibiotic exposure,
specifically cephalosporin and carbapenem use [20,21]. Our study,
on the other hand, identified previous hospital stay as a significant
independent predictor of ERE acquisition. This is not surprising as
this factor has been widely acknowledged to be associated with the
acquisition of several different types of antibiotic-resistant
organisms such as multi-drug resistant Acinetobacter baumanni, and
Pseudomonas aeruginosa [32,33]. Previously hospitalized patients will
have a higher likelihood of exposure to nosocomial organisms
through horizontal transmission among patients. Furthermore,
previous hospital stay could be a surrogate marker of prior
antibiotic exposure.
Long durations of fluoroquinolone exposure were also associ-
ated with the acquisition of ERE in our study. This association
offers biologic plausibility. Ertapenem resistance is commonly
mediated by the production of AmpC/ESBL enzymes coupled
with a deficiency in expression of the outer membrane proteins
(OMPs) [7–10]. In our study, 80% of available isolates tested
identified ESBL/AmpC as the prevalent mechanisms. There is a
possibility that fluoroquinolone use has resulted in a selective
pressure for these ESBL-producing Enterobacteriaceae in our
institution. In this population of ESBL-producing Enterobacteriaceae,
there could be an ertapenem-resistant subpopulation with
deficiency in porin expression. This phenomenon has been
demonstrated by Leavitt et al., where 1–2% of ESBL-producing
Klebsiella pneumonia in the study was found to be lacking in
Table 4. Antibiotic exposures
a as risk factors for ERE infections.
ERE ESE Control ERE versus controls ESE versus controls
(n=29) (n=29) (n=87) OR (95% CI) P OR (95% CI) P
Any antibiotic 28 (96.6) 24 (82.8) 62 (71.3) 11.29 (1.45–87.53) 0.005 1.94 (0.66–5.64) 0.22
Penicillins 7 (24.1) 5 (17.2) 13 (14.9) 1.81 (0.64–5.10) 0.26 1.19 (0.38–3.67) 0.77
Penicillins duration 0 (0–37) 0 (0–11) 0 (0–10) … 0.11 … 0.83
Beta-lactam/beta-lactamase inhibitors 23 (79.3) 12 (41.4) 41 (47.1) 5.39 (1.88–15.41) 0.001 0.79 (0.34–1.85) 0.29
Beta-lactam/beta-lactamase inhibitors duration 7 (0–30) 0 (0–23) 0 (0–31) … 0.004 … 0.96
3
rd-generation cephalosporins 18 (62.1) 14 (48.3) 27 (31.0) 3.64 (1.51–8.74) 0.003 2.07 (0.88–4.89) 0.09
3
rd-generation cephalosporins duration 3 (0–14) 0 (0–10) 0 (0–15) … 0.01 … 0.25
4
th-generation cephalosporins 7 (24.1) 4 (13.8) 1 (1.1) 32.76 (3.88–276.49) ,0.001 13.76 (1.47–128.75) 0.01
4
th-generation cephalosporins duration 0 (0–11) 0 (0–17) 0 (0–6) … 0.02 … 0.08
Ertapenem 3 (10.3) 1 (3.1) 0 … 0.01 … 0.25
Ertapenem duration 0 (0–25) 0 (0–9) 0 … 0.17 … 0.33
Anti-pseudomonal carbapenems 6 (20.7) 2 (6.9) 3 (3.4) 7.30 (1.70–31.47) 0.01 2.07 (0.33–13.07) 0.60
Anti-pseudomonal carbapenems duration 0 (0–28) 0 (0–7) 0 (0–12) … 0.07 … 0.47
Fluoroquinolones 12 (41.4) 5 (17.2) 17 (19.5) 2.91 (1.17–7.22) 0.02 0.86 (0.29–2.58) 0.78
Fluoroquinolones duration 0 (0–90) 0 (0–19) 0 (0–18) … 0.01 … 0.20
Aminoglycosides 8 (27.6) 1 (3.4) 4 (4.6) 7.91 (2.17–28.78) 0.002 0.74 (0.08–6.91) 1.00
Aminoglycosides duration 0 (0–12) 0 (0–6) 0 (0–5) … 0.02 … 0.60
The ERE-control model was conducted independently from the ESE-control model.
Categorical data are presented as n (%), while continuous data are presented as median days (range).
aDefined as receipt of $one dose of antimicrobials 90 days prior to Enterobacteriaceae isolation for case patients or end of hospitalization for control patients.
doi:10.1371/journal.pone.0034254.t004
Table 5. Multivariate model of risk factors for Enterobacteriaceae acquisition.
ERE versus controls ESE versus controls
OR (95% CI) P OR (95% CI) P
Previous hospital facility stay 10.40 (2.19–49.20) 0.003
Urinary catheter 9.70 (2.33–40.37) 0.002 3.33 (1.24–9.00) 0.02
Median duration of fluoroquinolone, days (range) 1.18 (1.05–1.34)
a 0.007
Median duration of 4
th-generation cephalosporin, days (range) 1.63 (1.05–2.54)
a 0.03
The ERE-control model was conducted independently from the ESE-control model. Other covariates not presented had a P value.0.05.
aOR corresponds to a unit increase in the continuous scale of the variable.
doi:10.1371/journal.pone.0034254.t005
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exposures, including ertapenem and the other carbapenems use,
then exert a selective pressure for these ESBL-producing
Enterobacteriaceae associated with porin loss, or facilitate the
activation of mechanisms leading to porin loss, resulting in the
predomination of ertapenem-resistant phenotypes.
Our study did highlight some key differences when compared to
the other ERE and CRE risk factor studies whereby poor
functional status; ICU stay; presence of biliary drains and invasive
ventilation; prior beta-lactams, anti-pseudomonal penicillins and
carbapenem exposure were identified as predictors [13–21]. These
discrepancies in findings were not unexpected since the profiles of
study organisms were largely different - some studies included both
colonized patients and those with clinically-relevant infections; and
sites and species of infecting organisms also varied. The resulting
epidemiological characteristics and resistance mechanisms of study
organisms were hence diverse. For instance, isolates from Israel
had a mix of KPC- and ESBL-producers with porin loss [14,16];
carbapenem-resistant strains from Greece were likely to be MBL-
producers [34]; US isolates consisted of KPC-producers [35–37];
while our local isolates were predominantly ESBL-producers,
likely with porin loss. This diversity in carbapenem resistance
mechanisms may be associated with distinct clinical risk factors, in
particular prior antibiotic exposure, explaining the differences
between the studies.
Not surprisingly, we showed that there is a significant difference
in in-hospital mortality and clinical response between the ERE
and ESE group. However, ERE infection was not found to be a
significant predictor of in-hospital mortality in the multivariate
analysis, probably due to the confounding effect of severity of
illness. A more extensive study with a larger sample size would
have to be undertaken to better characterize the clinical outcomes.
Our study presented with several limitations. First, this is a
retrospective study with a small sample size – only 29 cases in each
case group were collected, limiting the power of the study.
However, almost all adult hospitalized patients with an ERE
during the study period were included. Molecular characterization
of ERE was further limited to only 15 available isolates, hence
results may not have been representative of the true distribution of
resistance mechanisms locally. In addition, controls were not
screened for Enterobacteriaceae by active surveillance, some patients
with unrecognized Enterobacteriaceae colonization may be misclas-
sified as non-infected control patients. Our study also did not seek
to distinguish between colonization and infection with and ERE
Table 6. Outcomes for ERE and ESE infections.
Outcomes ERE (n=26) ESE (n=27) P
In-hospital mortality 8 (30.8) 2 (7.4) 0.04
Median hospital days
after infection, (range)
16 (1–107) 12 (2–163) 0.39
30-day readmission
a 7 (38.9) 9 (36.0) 0.30
Clinical response 17 (65.4) 24 (88.8) 0.04
aAnalyzed as percentage of patients who were discharged.
doi:10.1371/journal.pone.0034254.t006
Table 7. Univariate predictors of in-hospital mortality among ERE and ESE patients.
Died (n=10) Survived (n=43) OR (95% CI) P
Median age, yr (range) 62 (22–91) 69 (24–88) … 0.31
Male sex 7 (70.0) 19 (44.2) 1.94 (0.67–12.95) 0.18
Diabetes mellitus 6 (60.0) 17 (39.5) 2.29 (0.56–9.35) 0.30
Cardiovascular disease 5 (50.0) 17 (39.5) 1.53 (0.38–6.09) 0.72
Hepatic disease 2 (20.0) 7 (16.3) 1.29 (0.22–7.39) 1.00
Renal disease 2 (20.0) 17 (39.5) 0.38 (0.07–2.02) 0.30
Neurologic disease 2 (20.0) 8 (18.6) 1.09 (0.19–6.17) 1.00
Malignancy 5 (50.0) 6 (14.0) 6.17 (1.36–27.92) 0.02
Median Charlson score (range)
a 5 (2–13) 5 (0–12) … 0.90
Median APACHE II score, (range)
a 19 (12–30) 15 (2–46) … 0.05
Previous hospital stay 8 (80.0) 28 (65.1) 2.14 (0.40–11.40) 0.47
Previous ICU stay 2 (20.0) 7 (16.3) 1.28 (0.22–7.39) 1.00
Immunosuppression 3 (30.0) 6 (14.0) 2.64 (0.53–13.15) 0.35
Specimen type
Blood 5 (50.0) 7 (16.3) 5.14 (1.17–22.61) 0.04
Urine 2 (20.0) 18 (41.9) 0.35 (0.07–1.83) 0.29
Respiratory secretions 1 (10.0) 5 (11.6) 0.84 (0.09–8.15) 1.00
Skin/ Soft tissue 0 4 (9.3) … 1.00
Abdominal 2 (20.0) 9 (20.9) 0.94 (0.17–5.25) 1.00
ERE infection 8 (80.0) 18 (41.9) 5.55 (1.05–29.33) 0.04
Appropriate therapy
b 4 (40.0) 7 (16.3) 3.43 (0.76–15.40) 0.19
Data are presented as n(%), unless otherwise stated.
aMeasured on date of culture isolation for case patients and on date of admission for controls.
bDefined as receipt of an antibiotic which Enterobacteriaceae was susceptible to within 24 hours of culture.
doi:10.1371/journal.pone.0034254.t007
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clinical characteristics, and hence different risk factors.
As with many antimicrobial resistance epidemiological studies,
selection bias and confounding are issues of concern. The use of
controls without prior gram-negative bacillary infection, and with
possible gram-positive infection only, may have introduced a
selection bias towards potentially healthier controls. Furthermore,
there is a concern that use of such a control group may not
represent the true source population for the cases, and will not
allow the differentiation between ERE-specific risk factors and risk
factors relating to gram-negative bacilli infections in general.
Missing information on antibiotic treatments and instrumentation
at private healthcare providers prior admission, and the lack of
electronic randomization procedures could have also contributed
to selection bias. Finally, case and control patients were not
matched due to difficulties in obtaining matched controls for two
different case groups. This led to differences in certain variables
such as length of stay prior to outcome of interest, severity of illness
and age between the groups, all of which could potentially
confound the interpretation of results. The differences in the
median lengths of stay prior to outcome of interest between the
ERE group and the two other groups, is a possible study
limitation. However, it is also debatable, as a significantly longer
hospitalization may be needed to acquire ERE. Future studies
should be designed to control for these differences in length of stay.
In conclusion, we found that ERE infection was associated with
previous hospital stay and increased duration of prior fluoroquin-
olone therapy, notwithstanding the above limitations. Patients with
ERE infection experienced higher in-hospital mortality rates and
poorer clinical response. ERE represent a major clinical and
infection control challenge. Evidently, more active interventions
and research in this area is required to curb the problem. In
particular, the introduction of preventive measures such as
antimicrobial stewardship to help reduce unnecessary fluoroquin-
olones use may help to attenuate the risk of ERE infections.
Nosocomial transmission is a critical factor in the context of
carbapenem-resistant Enterobacteriaceae, and risk of horizontal
transmission during hospitalization can be alleviated by active
surveillance, good infection control practices such as hand hygiene
and cohorting measures. Further investigations on mechanisms of
resistance and clonal spread, as well as a more detailed analysis of
clinical outcomes are warranted for a better understanding of the
current problem.
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